<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904423</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-15005</org_study_id>
    <secondary_id>SU-09232008-1302</secondary_id>
    <secondary_id>BRSADJ0014</secondary_id>
    <nct_id>NCT00904423</nct_id>
  </id_info>
  <brief_title>Ph I/II of Vitamin D on Bone Mineral Density &amp; Markers of Bone Resorption</brief_title>
  <official_title>A Phase I/II Randomized, Double-blind, Controlled Study to Evaluate Efficacy and Safety of Vitamin D on Bone Mineral Density and Markers of Bone Resorption in Aromatase Inhibitor-induced Bone Loss in Women With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Pegram</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aromatase inhibitors are potent suppressors of breast cancer growth, but side effects include
      bone loss, fractures, arthralgias and myalgias. We hypothesize vitamin D administration might
      be beneficial in treating these symptoms and to protect bone.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spine Bone Mineral Density T Score Change Over One Year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hip Bone Mineral Density (BMD) T-score</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers</measure>
    <time_frame>months 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arthralgias and Myalgias</measure>
    <time_frame>every 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium and Fasting Spot Urine Calcium/Creatinine Ratio</measure>
    <time_frame>every 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Bone Diseases</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>up to 2400 mg; oral tablet</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Vital nutrients</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        3.1.1 All postmenopausal women with histology-confirmed invasive primary breast cancer, who
        have completed primary surgical or radiotherapy (XRT) with or without adjuvant chemotherapy
        and are candidates to receive adjuvant therapy with aromatase inhibitors will be screened
        for eligibility. Postmenopausal is defined as satisfying one or more of the following
        criteria: having had bilateral oophorectomy; aged more than 60 years; or aged 55-59 years
        with an intact uterus and amenorrheic for at least 12 months; or if amenorrheic for less
        than 12 months (after receiving hysterectomy, hormone therapy or chemotherapy).

        3.1.2 At the time of study enrollment, participants will have completed primary surgical or
        XRT with or without adjuvant chemotherapy. Chemotherapy will be completed at least 28 days
        prior to enrollment.

        3.1.4 Participants will be women between 18-85 years of age. Women and minorities will be
        actively recruited. Though breast cancer extremely rarely occurs in children and men, this
        study will only recruit adult females.

        3.1.5 Participants will have a life expectancy of at least 5 years.

        3.1.6 Participants will have Eastern Clinical Oncology Group (ECOG) performance status 0-2.

        3.1.7 Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

        3.2.1 Medications affecting bone metabolism (bisphosphonates, anticonvulsants, chronic
        heparin therapy, chronic glucocorticoid use &gt; 5 mg/day prednisone or equivalent,
        teriparatide).

        3.2.2 Use of any investigational drug within past 90 days.

        3.2.3 Metastatic breast cancer. High risk for osteoporosis/fractures (BMD &lt; -2.0, history
        of non-traumatic fracture). Hyperparathyroidism Hypercalcemia Hypercalciuria (fasting spot
        urine calcium/creatinine ratio &gt;0.20) History of renal stones Renal failure with creatinine
        over 2.0

        3.2.4 Considering that vitamin D3 is produced by the human body, allergy to vitamin D3 is
        not expected to develop. Subjects with known history of allergic reaction to compounds used
        to manufacture capsules (rice powder) will be excluded form this study.

        3.2.5 Recent history of excessive alcohol or drug use.

        3.2.6 As this study will recruit post-menopausal patients, thus pregnant or nursing
        patients are not part of this investigation.

        3.2.8 This study is designed to study women after completing primary therapy for breast
        cancer. Survivors of previous cancers and HIV-positive subjects will not be excluded.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Balint</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert W Carlson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <results_first_submitted>June 27, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2017</results_first_posted>
  <last_update_submitted>December 20, 2016</last_update_submitted>
  <last_update_submitted_qc>December 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Mark Pegram</investigator_full_name>
    <investigator_title>Susy Yuan-Huey Hung Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Bone Resorption</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spine Bone Mineral Density T Score Change Over One Year</title>
        <time_frame>1 year</time_frame>
        <population>Data are not accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: up to 2400 mg; oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Spine Bone Mineral Density T Score Change Over One Year</title>
          <population>Data are not accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hip Bone Mineral Density (BMD) T-score</title>
        <time_frame>one year</time_frame>
        <population>Data are not accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: up to 2400 mg; oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hip Bone Mineral Density (BMD) T-score</title>
          <population>Data are not accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Turnover Markers</title>
        <time_frame>months 4 and 12</time_frame>
        <population>Data are not accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: up to 2400 mg; oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Markers</title>
          <population>Data are not accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arthralgias and Myalgias</title>
        <time_frame>every 4 months</time_frame>
        <population>Data are not accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: up to 2400 mg; oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Arthralgias and Myalgias</title>
          <population>Data are not accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium and Fasting Spot Urine Calcium/Creatinine Ratio</title>
        <time_frame>every 4 months</time_frame>
        <population>Data are not accessible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D: up to 2400 mg; oral tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium and Fasting Spot Urine Calcium/Creatinine Ratio</title>
          <population>Data are not accessible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Adverse event data are not accessible.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D</title>
          <description>Vitamin D: up to 2400 mg; oral tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination secondary to low accrual.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark D Pegram, MD</name_or_title>
      <organization>Stanford Cancer Institute, Stanford University</organization>
      <phone>650-723-5801</phone>
      <email>mpegram@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

